Bot Detector
Download FREE Sample Issue or Article
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study

Author(s):  Glisson James K, Wood Rebecca L, Kyle Patrick B, Cleary John D

Issue:  May/Jun 2005 - Veterinary Compounding
View All Articles in Issue

Page(s):  242-246

Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study Page 1
Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study Page 2
Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study Page 3
Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study Page 4
Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study Page 5

Download in electronic PDF format for $75

Abstract:  The purpose of this open-label, nonrandomized, crossover trial was to determine the bioavailability of promethazine formulated in a topical Pluronic lecithin organogel. The study was performed at a tertiary care facility. The study subjects were 15 healthy adult white men aged 21 to 40 years, all of whom met the inclusion criteria. Volunteers with a medical history of promethazine hypersensitivity, epileptic disorder, or extrapyramidal reactions, or who had an abnormal skin condition or were taking any medications were excluded. Promethazine 50 mg in a Pluronic lecithin organogel was applied once to the skin of the nondominant wrist of each of 15 subjects, and the application site was covered with an adhesive bandage. Blood samples were collected at baseline (time zero) before drug administration and at 15, 30, 60, 120, 240, and 360 minutes after drug administration. After a 21-day washout period, 10 of the subjects returned for administration of a single dose of intravenous promethazine 25 mg, and blood samples were again collected at the same time intervals as after the topical dose. A high-performance liquid chromatographic method was used to determine serum concentrations of promethazine. The calculated absolute bioavailability of topical promethazine was 2%. Mean AUC0-8 were 16.63 ng•mL/hour for the topical preparation and 407.15 ng•mL/hour for the intravenous dose. At least 50% of the subjects who received the topical promethazine preparation experienced sedation and 73% experienced drowsiness; however, 100% of those who received intravenous promethazine experienced sedation. Although serum concentrations after application of topical promethazine were much lower than after parenteral administration, the study demonstrated that the topical promethazine formulation was absorbed systemically. These data suggest that further research regarding the bioavailability of promethazine in a topically applied Pluronic lecithin organogel is warranted. Clinical trials are needed that focus on the antiemetic efficacy of this formulation in similar and other populations.

Related Keywords: James K. Glisson, MD, PharmD, Rebecca L. Wood, PharmD, Patrick B. Kyle, John D. Cleary, PharmD, FCCP, promethazine, antiemetic, transdermal preparation, percutaneous drug delivery, emesis, nausea, vomiting, phenothiazine, Pluronic lecithin organogel, PLO, drug carrier, drug vehicle, bioavailability, topical preparation


Printer-Friendly Version

Related Articles from IJPC
(Click for Abstract / Details / Purchase)
Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study
Glisson James K
, Wood Rebecca L, Kyle Patrick B, Cleary John D
May/Jun 2005
Pg. 242-246

Veterinary Transdermal Medications: A to Z
Davidson Gigi S
Mar/Apr 2003
Pg. 106-113

Effect of Formulation pH on Transdermal Penetration of Antiemetics Formulated in Poloxamer Lecithin Organogel
Woodall Rachel
, Arnold John J, McKay Doug, Abill C Scott
May/Jun 2013
Pg. 247-253

Pluronic Lecithin Organogel for Local Delivery of Anti-Inflammatory Drugs
Frankum James
, Ramsay Dale, Das Nandita G, Das Sudip K
Mar/Apr 2004
Pg. 101-105

Incorporating Quality Assurance in Pharmaceutical Compounding-related Courses in the PharmD Curricula
Hossain Mohammad Faisal
, Levesque Dan, Frye John, Rashid Mamoon
Jul/Aug 2020
Pg. 322-326

Preparation and In Vitro Evaluation of a Pluronic Lecithin Organogel Containing Ricinoleic Acid for Transdermal Delivery
Boddu Sai HS
, Bonam Sindhu Prabha, Wei Yangjie, Alexander Kenneth
May/Jun 2014
Pg. 256-261

Novel Approaches to Topical Psoriasis Therapy
Koyama Gregory
, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
Sep/Oct 2015
Pg. 357-365

Evaluation of the Stability of Promethazine Hydrochloride in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date
Peacock Gina F
, Sauvageot Jurgita
Jul/Aug 2014
Pg. 345-347

The Use of Pluronic Lecithin Organogels in the Transdermal Delivery of Drugs
Bramwell Bethany L
, Williams LaVonn A
Jan/Feb 2012
Pg. 62-63

In Vitro Percutaneous Absorption of Ketoprofen and Testosterone: Comparison of Pluronic Lecithin Organogel vs. Pentravan Cream
Lehman Paul A
, Raney Sam G
May/Jun 2012
Pg. 248-252

Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Hong Eun Ji
, Sumanasekera Wasana, Le Uyen Minh
Jan/Feb 2022
Pg. 65-71

Finding the Right Balance: A Nationwide Study of Student Pharmacist Exposure to and Perceptions of Nonsterile Compounding
Fredrickson Mary E
, Belcher Faith G, Del Vecchio Kamryn N, Galleher Miranda N, Jugo Leila S, Gothard M David, Pallotta Raneem H, Pallotta Victor A Jr
May/Jun 2022
Pg. 242-247

Evaluation of the Percutaneous Absorption of Promethazine Hydrochloride, In Vitro, Using the Human Ex Vivo Skin Model
Bassani August S
, Banov Daniel, Lehman Paul A
May/Jun 2008
Pg. 270-273

Promethazine 25 mg/mL in Pluronic Lecithin Organogel for Nausea and Vomiting in a Pediatric Patient: A Case Report
Muller George
May/Jun 2009
Pg. 220-221

Stability Studies of Fludrocortisone Acetate Capsules and Fludrocortisone Acetate Titrated Powders (Powder Triturates)
Brandin Thibaut
, Wasilewski Maya, Panuccio Camille, Bouguergour Cyrielle, Primas Nicolas, Lamy Edouard, Jean Christophe, Bertault-Peres Pierre, Rathelot Pascal, Curti Christophe, Vanelle Patrice
Mar/Apr 2022
Pg. 150-154

In Vitro Permeability, Irritability, and Release Evaluation of Commonly Used Topical Diclofenac Gel Preparations (1%, 5%, and 10%)
Kohan Hamed Gilzad
, Baker David M, Sani Shabnam, Bielecki-Wilken Kathleen A, Ramirez Alfonso
Mar/Apr 2021
Pg. 146-155

Safe Cytotoxic Drug Preparation Using a Closed-system Transfer Device: Technical and Practical Evaluation of a New Device (Vialshield/Texium) Comparatively to a Reference One (Phaseal)
Garrigue Philippe
, Montana Marc, Ventre Christophe, Savry Amadine, Gauthier-Villano Laurence, Pisano Pascale, Pourroy Bertrand
Mar/Apr 2016
Pg. 148-154

Compounding for Diabetic Patients:An Interview with Paul Lofholm, PharmD
Allen Loyd V Jr
Nov/Dec 1997
Pg. 381-385

The Release and Transdermal Penetration of Baclofen Formulated in a Poloxamer Lecithin Organogel
Arnold John J
, Asbill Scott
Nov/Dec 2009
Pg. 569-571

Evaluation of Dosage Form Information Provided in Pediatric Drug Trial Reports
Haase Mark R
, Luedtke Sherry, Robles Janie, Parker Thomas, Leff Rich, Giacoia George
Jan/Feb 2009
Pg. 14-18

Return to Top